---
title: "Key facts: Wainua fails CV trial; Enhertu nears UK price deal"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292161190.md"
description: "AstraZeneca's Wainua failed its late-stage cardiovascular trial, showing no significant reduction in CV deaths or recurrent events. Meanwhile, AstraZeneca and Daiichi Sankyo are nearing a pricing deal with UK regulators for Enhertu to improve access for HER2-low metastatic breast cancer. Additionally, AstraZeneca partnered with PureHealth and Abu Dhabi Health to open a Rare Diseases Centre in Abu Dhabi."
datetime: "2026-07-09T07:14:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292161190.md)
  - [en](https://longbridge.com/en/news/292161190.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292161190.md)
generator: "portal-rs"
---

# Key facts: Wainua fails CV trial; Enhertu nears UK price deal

-   AstraZeneca’s AZN drug Wainua failed its late-stage cardiovascular trial: in 1,432 patients over 140 weeks, adding Wainua to standard care showed no significant cut in CV deaths or recurrent events 1
-   AstraZeneca, with Daiichi Sankyo, nears deal with UK regulator and NHS England on Enhertu price for HER2-low metastatic breast cancer to improve access across England, Wales and Northern Ireland 2
-   AstraZeneca (AZN) and Daiichi Sankyo nearing UK pricing and reimbursement deal for their breast cancer drug; negotiations focus on finalizing terms with UK health authorities. 3
-   AstraZeneca (AZN) partners with PureHealth and Abu Dhabi Health to open a Rare Diseases Centre in Abu Dhabi, focusing on diagnosis, lifelong care, treatment, research and real-world data generation. 4

### Related Stocks

- [AZN.UK](https://longbridge.com/en/quote/AZN.UK.md)
- [AZN.US](https://longbridge.com/en/quote/AZN.US.md)
- [DSNKY.US](https://longbridge.com/en/quote/DSNKY.US.md)
- [4568.JP](https://longbridge.com/en/quote/4568.JP.md)

## Related News & Research

- [AstraZeneca Reports Mixed Lung Cancer Trial Outcomes From Three Pivotal Studies](https://longbridge.com/en/news/296114723.md)
- [BREAKINGVIEWS-AstraZeneca's blocked M&A signals tough CEO finale](https://longbridge.com/en/news/296766497.md)
- [AstraZeneca halts lung cancer trial of volrustomig in latest blow to pipeline](https://longbridge.com/en/news/296069146.md)
- [04:03 ETDizal to Present Emerging Data on ZEGFROVY® in Non-Small Cell Lung Cancer at WCLC 2026](https://longbridge.com/en/news/296585269.md)
- [REG - AstraZeneca PLC - Update on eVOLVE-Lung02 Phase III trial](https://longbridge.com/en/news/296062318.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**